Inhibition of HIV-1 Replication in Transduced, G418-Selected LTBMC
| . | Inhibition at Peak Virus Production (%) . | Inhibition at Peak Virus Production (%) . | Inhibition at Peak Virus Production (%) . |
|---|---|---|---|
| . | L-RRE neo . | L-TR/TAT neo . | L-M10 SN . |
| HIV-1 JR FL challenge: | |||
| COH 1 (TD on NHS) | 95.20 | 98.00 | 98.00 |
| COH 2 (TD on NHS) | 92.70 | 87.20 | 99.90 |
| COH 2 (TD on NHS) | 99.90 | 99.70 | 99.90 |
| COH 3 (TD on NHS) | 94.70 | 75.40 | 99.80 |
| COH 5 (TD on NHS) | 44.20 | 99.90 | 99.90 |
| Inhibition range: | 44.2-99.9 | 75.4-99.9 | 98-99.9 |
| HIV-1 primary isolate challenge: | |||
| COH 5 (TD on NHS) | 98.50 | 99.90 | 99.90 |
| COH 5 (TD on HIV-str.) | 73.70 | 99.70 | 99.70 |
| COH 7 (TD on HIV-str.) | 98.40 | 99.60 | 98.60 |
| Inhibition range: | 73.3-98.5 | 99.6-99.9 | 98.6-99.9 |
| . | Inhibition at Peak Virus Production (%) . | Inhibition at Peak Virus Production (%) . | Inhibition at Peak Virus Production (%) . |
|---|---|---|---|
| . | L-RRE neo . | L-TR/TAT neo . | L-M10 SN . |
| HIV-1 JR FL challenge: | |||
| COH 1 (TD on NHS) | 95.20 | 98.00 | 98.00 |
| COH 2 (TD on NHS) | 92.70 | 87.20 | 99.90 |
| COH 2 (TD on NHS) | 99.90 | 99.70 | 99.90 |
| COH 3 (TD on NHS) | 94.70 | 75.40 | 99.80 |
| COH 5 (TD on NHS) | 44.20 | 99.90 | 99.90 |
| Inhibition range: | 44.2-99.9 | 75.4-99.9 | 98-99.9 |
| HIV-1 primary isolate challenge: | |||
| COH 5 (TD on NHS) | 98.50 | 99.90 | 99.90 |
| COH 5 (TD on HIV-str.) | 73.70 | 99.70 | 99.70 |
| COH 7 (TD on HIV-str.) | 98.40 | 99.60 | 98.60 |
| Inhibition range: | 73.3-98.5 | 99.6-99.9 | 98.6-99.9 |